Back to power alley stuff, this morning — as by my reckoning, this is at least seven high level departures from Rob Davy’s leadership team in just under five months.

Not that (in this tight market for real pharma executive market) good people don’t “test the waters” and listen to offers… but this is of concern, given what I know about his management style.

The departing talent was all assembled under Mr. Frazier, and his leadership style was far more team oriented than Mr. Davis’s. This is the sort of thing that slows growth, longer term — the training and back-filling, and distraction of having other good people take on “two jobs” for a period during transitions. We shall see — but Moderna is clearly getting a great lateral here — good news for them (per the fine reporting at FiercePharma), and her:

…On May 31, Arpa Garay will enter the Moderna fold as chief commercial officer, the company said Wednesday. As a member of the biotech’s executive committee, Garay will report to Moderna helmsman Stéphane Bancel.

At Merck, Garay is responsible for the company’s long-term portfolio strategy and global marketing for approved and pipeline products. She nabbed a promotion to her current position back in February….

It is particularly telling (in my view, at least) that she is leaving right after getting a (likely longer-term, hard fought-for) big promotion. So, do be excellent, to each other… smile.

नमस्ते